Pharma Stocks Dip As Pfizer, Merck Sustain Unexpected FDA Rejections
In this article:
Pfizer stock skidded Monday after the Food and Drug Administration rejected its rare-disease drug — leading a smaller decline for similarly jilted Merck.
Advertisement
Recommended Stories
Don't buy the dip in stocks just yet as a wave of selling is about to bring the market to a bottom, according to one of the biggest bulls on Wall Street
The S&P 500 could bottom out in the next month, according to Fundstrat's head of research Tom Lee.
Business Insider•Time to Pounce: 2 Superb Utility Stocks That Haven't Been This Cheap in at Least 10 Years
One of the fastest-growing utility stocks, along with "Wall Street's Greatest Dividend Stock," make for phenomenal buys right now.
Motley Fool•2 Popular Artificial Intelligence (AI) Stocks to Sell Before They Drop 29% and 77%, According to Certain Wall Street Analysts
Certain Wall Street analysts see substantial downside for shareholders of Tesla and Palantir Technologies.
Motley Fool•Tesla's EV success made it 'Magnificent.' It could also be its downfall.
Tesla's growth story was about leading the paradigm shift to EVs, and an affordable car was a part of that story. Now without it, the narrative has changed.
Yahoo Finance•Trump Media stock jumps for second day as company goes to battle with short sellers
Trump Media is advising investors on ways to prevent their shares from being loaned for a short-interest position.
Yahoo Finance•Here's What the Average Senior Couple Collects in Social Security Today
The number may be smaller than expected.
Motley Fool•Jamie Dimon Knew Subprime 'Could Go Up In Smoke'; Now He's Worried About An Artificial Economy 'Fueled by Government Deficit Spending'
In the chaos of the 2008 recession, perhaps no bank stood more prepared than Jamie Dimon's J.P Morgan Chase & Co. (NYSE:JPM). In advance of the crisis, Jamie Dimon realized that "underwriting standards were deteriorating across the industry," with late payments on subprime loans rising. In late 2006, the bank led his firm to exit Wall Street's hot subprime business, starting with a frantic call made to J.P. Morgan's vacationing Chief of Securitized Products where he said, "I really want you to w
Benzinga•The Most Active Stock Trader in Congress Is Buying Shares of This Magnificent Stock-Split Stock
Wall Street's most-prominent stock-split stock of 2024 has been purchased on three separate occasions by a lawmaker who completed over 4,200 trades last year.
Motley Fool•3 No-Brainer Stocks I'd Buy Right Now Without Hesitation
Plenty of stocks are still worth buying despite the S&P 500 sitting around all-time highs.
Motley Fool•Forget Nvidia: 2 Super Semiconductor Stocks to Buy Hand Over Fist, According to Wall Street
Wall Street pros are bullish on two hot chip stocks not named Nvidia.
Motley Fool•